An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Phase 2
Active, not recruiting
NCT02648997
| Condition | Meningiomas |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 40 participants |
|---|
| Interventions | Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, External Beam RT |
|---|
| Start date | Mar, 2016 |
|---|
| Completion date | Dec 1, 2024 |
|---|
| Results posted | Jan 26, 2026 |
|---|
Summary
This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
Number of Participants Without Disease Progression At Six Months Following Initiation Of Study Therapy
6 months · Participants
| Cohort 1 (Original Cohort): Nivolumab Monotherapy | 10 Participants |
|---|
| Cohort 2 - Dose Level 0: Nivolumab in Combination With Ipilimumab | 3 Participants |
|---|
| Cohort 2 - Dose Level 0A: Nivolumab in Combination With Ipilimumab | 10 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.